Welcome to our dedicated page for Blueprint Medicines SEC filings (Ticker: BPMC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing the science-heavy language in Blueprint Medicines’ SEC documents can feel like decoding a genomic sequence. Pipeline updates on selective kinase therapies, milestone payments from collaborations, and cash-runway disclosures are scattered across hundreds of pages. If finding that information in a 10-K or spotting insider buys before an FDA catalyst seems daunting, you’re not alone.
Stock Titan solves the problem. Our platform delivers AI-powered summaries that translate complex biotech terminology into plain English, then links you straight to the source form. Need the Blueprint Medicines quarterly earnings report 10-Q filing? One click. Curious about Blueprint Medicines insider trading Form 4 transactions or real-time alerts for Blueprint Medicines Form 4 insider transactions real-time? We surface them instantly. From a Blueprint Medicines annual report 10-K simplified to a Blueprint Medicines 8-K material events explained, our AI highlights what moves the stock.
Here’s what you can do on this page:
- Review every 10-K, 10-Q and 8-K with side-by-side Blueprint Medicines earnings report filing analysis
- Track Blueprint Medicines executive stock transactions Form 4 and monitor patterns before clinical readouts
- Dive into the Blueprint Medicines proxy statement executive compensation to see how management is rewarded for pipeline milestones
- Use our natural-language search—“understanding Blueprint Medicines SEC documents with AI” returns plain-spoken answers, not PDFs
Every filing posts within minutes of hitting EDGAR, and our expert layer explains valuation drivers like clinical trial spend, collaboration revenue and patent updates. Complex biotech filings, now clear and actionable.
Blueprint Medicines (BPMC) – Form 4 key points
Director Alexis Borisy reported the full disposition of his equity on 17 Jul 2025, the date Sanofi’s acquisition of Blueprint closed. Each share of common stock was exchanged for $129.00 cash plus one contingent value right (CVR) under the previously announced Merger Agreement. Table I records the tender of 74,160 shares (Code “U”), leaving 0 shares owned after the transaction. Table II shows cancellation of 46,545 stock options struck between $50.64 and $106.14; options became fully vested and converted into the right to receive the cash spread versus strike price plus one CVR per optioned share.
All restricted stock units were likewise canceled for the same consideration. As a result, Borisy now holds no direct or indirect interest in Blueprint securities, and Blueprint has become an indirect wholly owned subsidiary of Sanofi. The filing is administrative, confirming completion of the takeover rather than signaling new operational or valuation information.
Blueprint Medicines (BPMC) – Form 4 key points
Director Alexis Borisy reported the full disposition of his equity on 17 Jul 2025, the date Sanofi’s acquisition of Blueprint closed. Each share of common stock was exchanged for $129.00 cash plus one contingent value right (CVR) under the previously announced Merger Agreement. Table I records the tender of 74,160 shares (Code “U”), leaving 0 shares owned after the transaction. Table II shows cancellation of 46,545 stock options struck between $50.64 and $106.14; options became fully vested and converted into the right to receive the cash spread versus strike price plus one CVR per optioned share.
All restricted stock units were likewise canceled for the same consideration. As a result, Borisy now holds no direct or indirect interest in Blueprint securities, and Blueprint has become an indirect wholly owned subsidiary of Sanofi. The filing is administrative, confirming completion of the takeover rather than signaling new operational or valuation information.
Blueprint Medicines (BPMC) Form 4 confirms closing of Sanofi acquisition. On 07/17/2025 EVP & Chief Legal Officer Tracey L. McCain exchanged all equity interests under the merger agreement with Sanofi’s Aventis unit.
- Offer consideration: $129.00 cash per share plus one contingent value right (CVR).
- Common stock: 88,195 shares (incl. 259 ESPP) converted into cash + CVR; post-transaction beneficial ownership is 0 shares.
- Equity awards: 280,525 stock options (strike $28.36–$100.13), 51,103 RSUs and 21,353 PSUs fully vested, cancelled and exchanged for cash/CVRs or rolled into cash-based awards that continue to vest per merger terms.
Purchaser merged with BPMC on 07/17/2025, making BPMC an indirect wholly owned Sanofi subsidiary. The executive now holds no BPMC securities, signalling completion of the transaction and removal of insider equity alignment with the former standalone company.
Blueprint Medicines (BPMC) Form 4 confirms closing of Sanofi acquisition. On 07/17/2025 EVP & Chief Legal Officer Tracey L. McCain exchanged all equity interests under the merger agreement with Sanofi’s Aventis unit.
- Offer consideration: $129.00 cash per share plus one contingent value right (CVR).
- Common stock: 88,195 shares (incl. 259 ESPP) converted into cash + CVR; post-transaction beneficial ownership is 0 shares.
- Equity awards: 280,525 stock options (strike $28.36–$100.13), 51,103 RSUs and 21,353 PSUs fully vested, cancelled and exchanged for cash/CVRs or rolled into cash-based awards that continue to vest per merger terms.
Purchaser merged with BPMC on 07/17/2025, making BPMC an indirect wholly owned Sanofi subsidiary. The executive now holds no BPMC securities, signalling completion of the transaction and removal of insider equity alignment with the former standalone company.
Blueprint Medicines (BPMC) Form 4 confirms closing of Sanofi acquisition. On 07/17/2025 EVP & Chief Legal Officer Tracey L. McCain exchanged all equity interests under the merger agreement with Sanofi’s Aventis unit.
- Offer consideration: $129.00 cash per share plus one contingent value right (CVR).
- Common stock: 88,195 shares (incl. 259 ESPP) converted into cash + CVR; post-transaction beneficial ownership is 0 shares.
- Equity awards: 280,525 stock options (strike $28.36–$100.13), 51,103 RSUs and 21,353 PSUs fully vested, cancelled and exchanged for cash/CVRs or rolled into cash-based awards that continue to vest per merger terms.
Purchaser merged with BPMC on 07/17/2025, making BPMC an indirect wholly owned Sanofi subsidiary. The executive now holds no BPMC securities, signalling completion of the transaction and removal of insider equity alignment with the former standalone company.
Blueprint Medicines (BPMC) Form 4 confirms closing of Sanofi acquisition. On 07/17/2025 EVP & Chief Legal Officer Tracey L. McCain exchanged all equity interests under the merger agreement with Sanofi’s Aventis unit.
- Offer consideration: $129.00 cash per share plus one contingent value right (CVR).
- Common stock: 88,195 shares (incl. 259 ESPP) converted into cash + CVR; post-transaction beneficial ownership is 0 shares.
- Equity awards: 280,525 stock options (strike $28.36–$100.13), 51,103 RSUs and 21,353 PSUs fully vested, cancelled and exchanged for cash/CVRs or rolled into cash-based awards that continue to vest per merger terms.
Purchaser merged with BPMC on 07/17/2025, making BPMC an indirect wholly owned Sanofi subsidiary. The executive now holds no BPMC securities, signalling completion of the transaction and removal of insider equity alignment with the former standalone company.
Blueprint Medicines (BPMC) – Form 4 snapshot: Director Jeffrey W. Albers reported the disposition of 144,755 common shares and the cancellation of all outstanding equity awards on 17 Jul 2025, the date Sanofi’s acquisition of BPMC closed.
Under the Merger Agreement, Sanofi paid $129.00 in cash per share plus one contingent value right (CVR). Each Albers RSU automatically converted into the cash + CVR consideration, and every stock option—including 92,500 options at $36.05 and 170,000 at $81.44—became fully vested and was cashed out for the in-the-money value plus a CVR per underlying share. After settlement, Albers reports 0 shares and 0 derivative securities, ending his beneficial ownership.
The filing confirms final equity clean-up following Sanofi’s tender offer and merger, leaving BPMC an indirect wholly-owned Sanofi subsidiary.
Blueprint Medicines (BPMC) – Form 4 snapshot: Director Jeffrey W. Albers reported the disposition of 144,755 common shares and the cancellation of all outstanding equity awards on 17 Jul 2025, the date Sanofi’s acquisition of BPMC closed.
Under the Merger Agreement, Sanofi paid $129.00 in cash per share plus one contingent value right (CVR). Each Albers RSU automatically converted into the cash + CVR consideration, and every stock option—including 92,500 options at $36.05 and 170,000 at $81.44—became fully vested and was cashed out for the in-the-money value plus a CVR per underlying share. After settlement, Albers reports 0 shares and 0 derivative securities, ending his beneficial ownership.
The filing confirms final equity clean-up following Sanofi’s tender offer and merger, leaving BPMC an indirect wholly-owned Sanofi subsidiary.
Blueprint Medicines (BPMC) – Form 4 snapshot: Director Jeffrey W. Albers reported the disposition of 144,755 common shares and the cancellation of all outstanding equity awards on 17 Jul 2025, the date Sanofi’s acquisition of BPMC closed.
Under the Merger Agreement, Sanofi paid $129.00 in cash per share plus one contingent value right (CVR). Each Albers RSU automatically converted into the cash + CVR consideration, and every stock option—including 92,500 options at $36.05 and 170,000 at $81.44—became fully vested and was cashed out for the in-the-money value plus a CVR per underlying share. After settlement, Albers reports 0 shares and 0 derivative securities, ending his beneficial ownership.
The filing confirms final equity clean-up following Sanofi’s tender offer and merger, leaving BPMC an indirect wholly-owned Sanofi subsidiary.
Schedule 13G filing – Blueprint Medicines Corp. (BPMC)
Hedge-fund complex Davidson Kempner and affiliates (M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP and managing member Anthony A. Yoseloff) disclose beneficial ownership of 0 shares and 0% of BPMC common stock as of the 14 Jul 2025 reportable event. Rows 5-8 of each cover page show no sole or shared voting or dispositive power. Item 5 confirms they now hold “5 percent or less” of the class. Historically, the group previously exceeded the 5 % threshold, triggering the original 13G; this amendment reflects a complete exit or reduction below the reporting threshold.
All reporting persons list the same business address (9 W 57th St., New York) and certify the shares were not acquired to influence control. The filing therefore signals that a significant institutional holder has fully unwound its position in Blueprint Medicines.
FAQ
What is the current stock price of Blueprint Medicines (BPMC)?
What is the market cap of Blueprint Medicines (BPMC)?
What is Blueprint Medicines Corp focused on?
How does the company differentiate its approach in drug discovery?
What are the core therapeutic areas of Blueprint Medicines?
How does Blueprint Medicines generate revenue?
What is unique about their research and development process?
How does Blueprint Medicines address unmet medical needs?
What role do kinase inhibitors play in their treatment strategy?
How does the company maintain its market position?
